Dr. Daniel Judge and Dr. C. Michael Gibson discuss data presented at ACC 2025: In Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR Levels sponsored by BridgeBio Pharma, Inc.